Antibody response assessment of immediate breakthrough infections after zero-COVID policy adjustment in China
Lancet Reg Health West Pac
.
2023 Nov 15:40:100945.
doi: 10.1016/j.lanwpc.2023.100945.
eCollection 2023 Nov.
Authors
Yanhua Li
1
,
Shitong Qiao
1
,
Lei Dong
2
,
Rong Zhang
3
,
Ruiqiang Li
4
,
Shijie Qin
1
,
Dongshan Yu
5
,
Xianfei Liu
6
,
Ying Li
2
,
Yueyun Ma
2
,
Xin Zhao
1
,
George Fu Gao
1
Affiliations
1
Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.
2
Department of Clinical Laboratory, Air Force Medical Center, Beijing, China.
3
Guangxi University State Key Laboratory for Conservation and Utilization of Subtropical Agro BioResources, Nanning, China.
4
Guangzhou Institutes of Biomedicine and Health Chinese Academy of Sciences, Guangzhou, China.
5
Department of Infectious Diseases, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
6
Department of Clinical Laboratory, The Second Affiliated Hospital of Nanhua University, Hengyang, China.
PMID:
38033432
PMCID:
PMC10684796
DOI:
10.1016/j.lanwpc.2023.100945
No abstract available